Radiomic Markers for Breast Cancer Metastasis and Treatment Response Using MRI

Official Title

Radiomic Markers for Breast Cancer Metastasis Using Dynamic Contrast Enhanced MRI and Diffusion-Weighted MRI


The primary aim of the study is to identify radiomic features as biomarkers of metastatic progression following primary therapy.

Trial Description

Primary Outcome:

  • Pathologic complete response (pCR)
Secondary Outcome:
  • Time to distant breast cancer recurrence (months)
  • Time to distant metastasis
  • Time to death
The study aims to evaluate radiomic markers in breast tumours to evaluate metastatic risk based on radiomic features following primary therapy. The investigators aim to analyze images at various time intervals before, during and after primary treatments using two advanced imaging techniques (DCE-MRI & DWI-MRI).

View this trial on

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society